Pancreatic neuroendocrine tumors (pNETs) are frequently malignant (50-80%, except for insulinoma) and may show an aggressive course with metastases to the liver as well as more distant sites. These heterogeneous neoplasms include functioning tumors, which secrete a variety of peptide hormones, and non-functioning tumors (up to 90% of pNETs), which often show metastases at the time of diagnosis.
Therapy for metastatic pancreatic neuroendocrine tumors / Rossi, R. E.; Massironi, S.; Conte, D.; Peracchi, M.. - In: ANNALS OF TRANSLATIONAL MEDICINE. - ISSN 2305-5839. - 2:1(2014), pp. 1-12. [10.3978/j.issn.2305-5839.2013.03.01]
Therapy for metastatic pancreatic neuroendocrine tumors
S. Massironi;
2014-01-01
Abstract
Pancreatic neuroendocrine tumors (pNETs) are frequently malignant (50-80%, except for insulinoma) and may show an aggressive course with metastases to the liver as well as more distant sites. These heterogeneous neoplasms include functioning tumors, which secrete a variety of peptide hormones, and non-functioning tumors (up to 90% of pNETs), which often show metastases at the time of diagnosis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
